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Abstract: Efficient syntheses of some new substituted pyrazoline derivatives 
linked to substituted benzimidazole scaffold were performed by multistep 
reaction sequences. All the synthesized compounds were characterized using 
elemental analysis and spectral studies (IR, 1D/2D NMR techniques and mass 
spectrometry). The synthesized compounds were screened for their antimicro-
bial activity against selected Gram-positive and Gram-negative bacteria, and 
fungi strain. The compounds with halo substituted phenyl group at C5 of the 
1-phenyl pyrazoline ring (15, 16 and 17) showed significant antibacterial acti-
vity. Among the screened compounds, 17 showed most potent inhibitory acti-
vity (MIC = 64 µg mL-1) against a bacterial strain. The tested compounds were 
found to be almost inactive against the fungal strain C. albicans, apart from 
pyrazoline-1-carbothiomide 21, which was moderately active. 
Keywords: chlacone; pyrazoline; diastereotopic protons; antibacterial activity; 
antifungal activity. 
INTRODUCTION 
In the current scenario, bacterial infections bring about a serious threat to 
human lives due to their rapid resistance to existing antibiotics. Thus, exploration 
of new types of antibacterial agents has become extremely vital. Benzimidazole 
derivatives are very useful for the development of molecules of pharmaceutical 
interest due to their pharmacological activities, including antimicrobial,1–3 anti-
cancer,4–6 antidiabetic7 and plasmin inhibitor.8 Moreover, N-benzyl-substituted 
benzimidazoles have been synthesized showing promising antibacterial activities, 
among which amidine9 I and 2-(piperidin-4-yl)benzimidazole10 II are examples 
(Fig. 1).  
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Fig. 1. Structures of some benzimidazoles and pyrazolines with antibacterial activity. 
The pyrazoline motif is a core structure in numerous biologically active 
compounds. Some representatives of this heterocycle exhibited antimicro-
bial,11,12 anticancer,13,14 anti-inflammatory,15,16 and monoamine oxidase inhib-
itory17,18 activities. Series of novel thiazolyl-pyrazoline,19 such as III and mor-
pholinoquinoline clubbed pyrazoline20 IV were recently reported as potent 
antibacterial agents (Fig. 1). The combination of N-benzylbenzimidazole and 
pyrazoline fragments in one molecule is expected to be a perspective approach to 
design promising antimicrobial agents. Thus, a novel series of N-benzyl attached 
benzimidazolyl pyrazolines was designed, synthesized and evaluated against 
different bacteria and fungi. 
EXPERIMENTAL 
Chemistry  
The chemicals used were laboratory grade and procured from Merck (India), Fischer 
Scientific (India) and Finar (India). IR spectra were obtained on a Bruker ALPHA-T FT-IR 
spectrometer (KBr pellets using opus software). 1H- and 13C-NMR spectra were recorded on a 
Bruker AVANCE III 500 MHz (AV 500) spectrometer using TMS as an internal standard in 
DMSO-d6/CDCl3. The mass spectra were recorded on a Varian Inc 410 Prostar Binary LC– 
–MS and an Agilent 6410 LC–MS spectrometer. Melting points were determined by the open 
tube capillary method and are uncorrected. Progress of the reaction and purity of the products 
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was checked by thin layer chromatography (TLC). The spots were located under iodine vap-
ours/UV light. The physical, analytical and spectral data for the compounds are given in the 
Supplementary material to this paper. 
General procedure for synthesis of 3-aryl-1-(1-benzyl-1H-benzo[d]imidazol-2-yl)-2-propen-1- 
-ones (8–12) 
Chalcones 3–7 (10 mmol) were dissolved in 40 mL dry acetone and then anhydrous 
K2CO3 (15 mmol) was added to the solution. Later benzyl chloride (40 mmol) was added to 
the mixture and the contents were heated under reflux. The progress of the reaction was moni-
tored by TLC (benzene–ethyl acetate, 4:1). After completion of the reaction (22–26 h), the 
reaction mixture was cooled and then poured into crushed ice. The obtained solid were filtered 
and recrystallized form alcohol. It should be noted that compounds 9– 11 crystallised out from 
the reaction mixture after cooling, and they were then collected by filtration. Compounds 8 
and 10 were previously reported.21 However, neither of them has been examined for their anti-
microbial activities. 
General procedure for the synthesis of 1-benzyl-2-(5-aryl-1-phenyl-4,5-dihydro-1H-pyrazol- 
-3-yl)-1H-benzimidazoles (13–17) 
To a solution of chalcones 8–12 (2 mmol) in acetic acid, phenylhydrazine (3 mmol) was 
added dropwise. The reaction mixture was heated under reflux. The progress of the reaction 
was monitored by TLC (benzene–ethyl acetate, 5:1). After completion of reaction (6–8 h), the 
reaction mixture was cooled and then poured into crushed ice. The obtained solid pyrazolines 
were washed with diethyl ether and recrystallized from acetone. 
General procedure for synthesis of 5-aryl-3-(1-benzyl-1H-benzimidazol-2-yl)-4,5-dihydro- 
-1H-pyrazole-1-carbothioamides (18–22) 
A mixture of chalcones 8–12 (2 mmol), thiosemicarbazide (6 mmol) and NaOH (4 mmol) 
was refluxed in ethanol (15 ml). The progress of the reaction was monitored by TLC (ben-
zene–ethyl acetate, 5:1). After completion of reaction (4–6 h), the reaction mixture was cooled. 
The precipitate formed was filtered and washed with acetone. 
Microbiology 
The compounds 8–22 were evaluated for their in vitro antimicrobial activity against bac-
terial strains, viz. Bacillus subtilis MTCC 441, Staphylococcus aureus MTCC 3160, Pseudo-
monas aeruginosa MTCC 4673 and Escherichia coli MTCC 739, and the fungi Candida 
albicans MTCC 183. The reference cultures were procured from the Institute of Microbial 
Technology (IMTECH), Chandigarh, India-160036. Minimum inhibitory concentrations 
(MIC) were determined using nutrient broth (NB) for the bacteria and Sabouraud dextrose 
broth (SDB) for fungi by the two-fold serial dilution method.22,23 The cultures were incubated 
for 24 h for the bacteria and 48 h for the fungi at 35 °C and the growth was monitored. The 
lowest concentration required to arrest the growth of microorganism was regarded as the mini-
mum inhibitory concentration (MIC). Ciprofloxacin and fluconazole were used as positive 
control for the bacteria and fungi, respectively. DMSO was used as the negative control. The 
determinations of the antimicrobial activities of the compounds were performed in duplicate. 
RESULTS AND DISCUSSION 
Chemistry 
The target compounds described in this study were prepared as outlined in 
Scheme 1. Condensation of o-phenylenediamine with lactic acid under Phillips 
Available on line at www.shd.org.rs/JSCS/_________________________________________________________________________________________________________________________
(CC) 2017 SCS
988 PADHY, PANDA and BEHERA 
conditions led to 2-(1-hydroxyethyl)benzimidazole (1), chromic oxidation of the 
latter followed by neutralization with ammonia led to 2-acetylbenzimidazole 
(2).24 The required synthons 3-aryl-1-(1H-benzimidazol-2-yl)-2-propen-1-ones 
(3–7) were prepared by Claisen–Schmidt condensation of 2-acetylbezimidazole 
with substituted aromatic aldehydes in presence of NaOH.25 Condensation of the 
3-aryl-1-benzimidazolyl-2-propen-1-one derivatives 3–7 with benzyl chloride 
gave the corresponding 3-aryl-1-(1-benzyl-1H-benzimidazol-2-yl)-2-propen-1- 
-ones 8–12. The reaction of 8–12 with phenylhydrazine in the presence of acetic 
acid afforded 1-benzyl-2-(5-aryl-1-phenyl-4,5-dihydro-1H-pyrazol-3-yl)-1H-ben-
zimidazoles 13–17, whereas when 8–12 were condensed with thiosemicarbazide 
in presence of NaOH, 5-aryl-3-(1-benzyl-1H-benzimidazol-2-yl)-4,5-dihydro- 
-1H-pyrazole-1-carbothioamides 18–22 were obtained in good yields. 
 
Scheme 1. Synthetic route to 1-benzyl-2-(1-substituted-5-aryl-4,5-dihydro-1H-pyrazol-3-yl)- 
-1H-benzimidazoles. Reagents and conditions: i) 4 M HCl, reflux, 8 h; ii) K2Cr2O7, dil. 
H2SO4, r.t., 2h; iii) Ar-CHO, 10 % aq NaOH, ethanol, r.t., 4–8 h; iv) benzyl chloride, dry 
acetone, anhydrous K2CO3, reflux, 22–26 h; v) phenylhydrazine, acetic acid, reflux, 6–8 h; 
vi) thiosemicarbazide, NaOH, ethanol, reflux, 4–6 h. 
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The structure of the synthesized compounds 8–22 were assigned based on 
elemental and spectroscopic analysis, IR, 1H-NMR, 13C-NMR and mass spec-
trometry (Supplementary material to this paper). The IR data were very inform-
ative and fully supported the proposed structures of the reported compounds. In 
the IR spectra of chalcones 8–12, the (C=O) stretching was found in the expected 
region at 1652–1662 cm–1. Furthermore, the presence of (C=N) and (C–N) 
stretching frequencies at 1594–1597 cm–1 and 1283–1330 cm–1 in the IR spectra 
of 13–22 confirmed the subsequent cyclization of the chalcone to the pyrazoline 
derivatives. In addition, derivatives 18––22 showed typical absorption bands due 
to (–NH2) at 3290–3355 cm–1 and 3218–3250 cm–1.  
The 1H-NMR spectrum compounds 8–12 exhibited two doublets with J 
values between 15–20 Hz, confirming the trans coupling and indicating the ole-
finic protons in the E form. The 13C-NMR spectra of 8–12 confirmed the pre-
sence of the α,β-unsaturated carbonyl system of chalcones by the presence of a 
peak at δ 182.40–182.53 ppm, corresponding to the propenone C1. 
Although compounds 13–22 were racemates, their structures were unambig-
uously assigned with the help of spectral studies. The 1H-NMR spectra of com-
pounds 13–22 displayed three sets of signals with an ABX pattern for the pyra-
zoline ring protons. The sterochemical nature of the hydrogens HA, HB and HX 
was ascertained from a study of the coupling constants (J). The vicinal coupling 
constant between HA and HX was found to be 2.7–10.0 Hz (JAX), which indi-
cates that these hydrogens are cis to each other, while the trans relationship 
between HB and HX was evident from the coupling constants of JBX in the 10.0– 
–15.0 Hz range. The coupling value of JAB in 17.5–20.0 Hz range between HA 
and HB evidently indicates their geminal placement at C4. The CH2 protons of 
pyrazoline are diastereotopic and appeared as a pair of doublets of doublets at δ 
2.90–3.10 ppm (HA) and δ 3.85–4.05 ppm (HB), due to the vicinal coupling with 
the HX proton and the geminal coupling with each other. The CH proton (HX) 
appeared as a doublet of doublets at δ 5.72–5.92 ppm due to vicinal coupling 
with the two magnetically non-equivalent protons of the methylene group (HA 
and HB) at position 4 of the pyrazoline ring. The two methylene protons of 
benzyl group on geminal coupling showed two separate doublets at δ 5.33–6.08 
ppm (HC) and δ 5.37–6.17 ppm (HD), indicating the diastereotopic nature of the 
methylene hydrogen. This was further confirmed by the appearance of three sets 
of signals at δ 40.03–44.45 ppm (C4 of pyrazoline), δ 47.01–48.18 ppm (CH2 of 
benzyl) and δ 57.54–62.62 ppm (C5 of pyrazoline) in the 13C-NMR spectra of 
pyrazolines. It should be noted that in the spectra of compounds 15 and 17, the 
signal of C4 of pyrazoline was overshadowed by residual peaks of DMSO-d6. 
Compounds 18–22 exhibited two separate broad singlets at δ 7.81–7.89 ppm and 
δ 8.26–8.38 ppm for the –NH2 protons. All the other additional peaks observed 
were in agreement with the respective aromatic substituents and benzimidazole 
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ring. The mass spectra and elemental analyses were also in agreement with the 
proposed structures. 
Furthermore, the carbon–proton correlation of pyrazoline 13 was confirmed 
by an HSQC experiment. The HA and HB protons (δ 3.06 and 3.71 ppm) showed 
a cross-peak with the carbon signal at 40.03 ppm, which confirmed that this 
signal is due to the C4 carbon. Similarly, the doublet of doublets at δ 5.75 ppm is 
strongly correlated with the carbon resonance at δ 60.36 ppm. From this, it is 
inferred that the carbon signal is due to the C5 carbon. The carbon signal at δ 
47.35 ppm correlated well with the two methylene protons (δ 5.34 and 5.39 ppm) 
of the benzyl group, which established the diastereotopic nature of the methylene 
hydrogens.  
Antimicrobial activity 
The synthesized compounds 8–22 were screened for their in vitro antimic-
robial activity. The results of antimicrobial activities of the benzimidazole deri-
vatives are presented in Table I. The antimicrobial screening data revealed that 
all the newly synthesized compounds exhibited weaker antimicrobial activities 
compared to those of the control drugs. For bacterial strains, the MIC values of 
the compounds ranged between 128–1024 μg mL–1 for the chalcones 8–12, 
between 64–1024 μg mL–1 for the 1-phenylpyrazolines 13–17 and between 128– 
–512 μg mL–1 for the pyrazoline-1-carbothioamides 18–22. Among all the tested 
compounds, compound 17 showed good activity (64 µg mL–1) against the tested 
bacterial strains. The MIC value of ciprofloxacin was 6.25–12.5 μg mL–1 for all 
TABLE I. In vitro antimicrobial activity of the synthesized compounds 8–22, MIC / µg mL-1 
Compound Gram-positive bacteria Gram-negative bacteria Fungi 
S. aureus B. subtilis E. coli P. aeruginosa C. albicans 
8 512 512 ˃1024 ˃1024 ˃1024 
9 ˃1024 512 ˃1024 ˃1024 ˃1024 
10 256 256 512 512 ˃1024 
11 128 256 256 512 ˃1024 
12 128 128 256 256 ˃1024 
13 256 512 512 256 ˃1024 
14 ˃1024 512 ˃1024 ˃1024 ˃1024 
15 64 128 256 128 512 
16 128 64 256 128 512 
17 64 128 64 256 256 
18 ˃1024 512 ˃1024 ˃1024 512 
19 ˃1024 ˃1024 512 ˃1024 512 
20 512 256 ˃1024 512 512 
21 256 128 512 512 128 
22 128 128 256 512 256 
Ciprofloxacin 6.25 6.25 6.25 12.5 – 
Fluconazole – – – – 6.25 
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the tested bacterial strains. Chalcones 8–12 and 1-phenylpyrazolines 13 and 14 
were almost inactive against C. albicans but pyrazoline-1-carbothioamide 21 
showed moderate activity against the fungi strain. The MIC value of fluconazole 
was 6.25 μg mL–1 for the fungi C. albicans. 
Subsequently, preliminary SAR studies were performed to deduce how the 
structure variation and modification could affect the antimicrobial activity. The 
antimicrobial activities of the compounds are related to the presence of electron 
withdrawing or donating substituents on the benzene ring. Compounds contain-
ing electron withdrawing –F, –Cl and –Br exhibited good antimicrobial activity, 
whereas non-substituted compounds and compounds substituted with electron 
donating groups did not exhibit the same potency. For example, compound 17 
showed an MIC of 64 µg mL–1 against S. aureus and E. coli, whereas compound 
13 showed an MIC of 256 and 512 µg mL–1, respectively. The reason for above 
antibacterial activities could be explained by electron density, which plays an 
important role for the optimum activity.  
CONCLUSIONS 
In this paper, the synthesis and characterization of three new chalcones, five 
1-phenylpyrazolines and five pyrazoline-1-carbothioamides containing the N-ben-
zylbenzimidazole moiety are presented. The structures of the new compounds 
were confirmed by spectral data (IR, 1H-NMR, 13C-NMR and mass spectro-
metry) and elemental analysis. All the compounds were investigated for their 
antimicrobial activity against B. subtilis, S. aureus, P. aeruginosa, E. coli and C. 
albicans. The data indicated weak antibacterial activity, except for compound 17 
(which presented good activity against S. aureus and E. coli), 16 (which pre-
sented moderate activity on S. aureus and P. aeruginosa and 15 (which presented 
moderate action on B. subtilis and P. aeruginosa). The weak antibacterial activity 
could be because the tested compounds were in a racemic form. Based on the 
MIC values presented by the tested compounds, it could be concluded that, in gen-
eral, the derivatives containing a fluorine, chlorine and bromine atom had better 
antibacterial activity against the tested strains. The tested compounds were found 
to be either inactive, or moderately active (21), against the fungal strain C. albicans. 
SUPPLEMENTARY MATERIAL 
Analytical and spectral data of the synthesized compounds are available electronically at 
the pages of the journal website: http://www.shd.org.rs/JSCS/, or from the corresponding 
author on request. 
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И З В О Д  
СИНТЕЗА И КАРАКТЕРИЗАЦИЈА НОВИХ БЕНЗИМИДАЗОЛА КОЈИ САДРЖЕ 
1,3,5-ТРИСУПСТИТУИСАНИ ПИРАЗОЛИН КАО АНТИМИКРОБНИХ ЈЕДИЊЕЊА 
GOPAL K. PADHY1,2, JAGADEESH PANDA3 и AJAYA K BEHERA1 
1Organic Synthesis Laboratory, School of Chemistry, Sambalpur University, Jyoti Vihar, Burla 768019, 
India, 2Maharajah’s College of Pharmacy, Phool Baugh, Vizianagaram 535002, India и 3Raghu College of 
Pharmacy, Dakamarri, Visakhapatnam 531162, India 
Извршена је ефикасна синтеза нових супституисаних деривата пиразолина везаних 
са бензимидазолским прстеном, применом вишефазне реакционе секвенције. Сва синте-
тисана једињења окарактерисана су елементалном анализом, спектроскопским мето-
дама (IR, 1D/2D NMR) и масеном спектрометријом. Испитана је антимикробна актив-
ност синтетисаних једињења према одабраним сојевима Грам-позитивних и Грам-нега-
тивних бактерија и одабраних сојева гљивица. Једињења која поседују халоген-супсти-
туисану ароматичну групу на C5 1-фенилпиразолинског прстена (15–17) показују зна-
чајну антибактеријску активност. Од испитиваних једињења, дериват 17 показује највећу 
инхибиторну активност (MIC = 64 μg mL-1). Испитивана једињења су показала готово 
потпуно одсуство активности према C. albicans, осим пиразолин-1-карботиоамида 21 
који је показао умерену активност. 
(Примљено 4. јуна 2016, ревидирано 3. априла, прихваћено 17. јула 2017) 
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